Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Thermo Fisher Scientific

Two healthcare giants - Danaher and Thermo Fisher - are finally trading at a fair price. Over the last decades, both companies shown a great track record of excellent operations.

Danaher And Thermo Fisher: Buy These High-Quality Compounders At A Fair Price

Lockheed Martin

Microsoft

PepsiCo

Raytheon Technologies

Unilever

The safest blue-chip stocks have strong catalysts bolstering their upside. As inflation soars, investing in these stocks makes more sense.

The 7 Safest Blue-Chip Stocks You Can Buy Now

Marubeni Corp

MARUY vs. DHR: Which Stock Is the Better Value Option?

MARUY or DHR: Which Is the Better Value Stock Right Now?

ION Acquisition Corp 3 Ltd

Membership Collective Group

TransDigm

UnitedHealth Group

According to the All-in-One Screener, a Premium feature of GuruFocus, five stocks that Ron Baron (Trades, Portfolio) and Daniel Loeb (Trades, Portfolio) both agree on and have outperformed the Standard & Poor's 500 index over the past three months are UnitedHealth Group Inc. ( UNH , Financial), Danaher Corp. ( DHR , Financial), TransDigm Group Inc. ( TDG , Financial), Membership Collective Group Inc. ( MCG , Financial) and ION Acquisition Corp. 3 Ltd. ( IACC , Financial).

5 High-Performing Stocks Ron Baron and Daniel Loeb Both Own

Chevron

McDonald's

AT&T

Blue-chip stocks are a smart choice during times when economic uncertainty is expected. So, here are seven blue-chip stocks to buy right now.

7 Blue-Chip Stocks to Buy for June 2022

FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #ASMS--SCIEX launches the next generation of Data Independent Acquisition with Zeno SWATH DIA at ASMS 2022.

SCIEX Launches the Next Generation of Data Independent Acquisition With Zeno SWATH DIA at ASMS 2022

FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #ASMS--SCIEX launches the new cornerstone of software ecosystem - SCIEX OS 3.0 - featuring Zeno SWATH DIA, stMRM and accessibility across 9 languages.

SCIEX Launches the New Cornerstone of Software Ecosystem - SCIEX OS 3.0

ConocoPhillips

Marvell Technology

NVIDIA

Workday

TipRanks analyst ranking service pinpoints Wall Street's picks for best-performing stocks, including Nvidia and Marvell.

Top Wall Street analysts are gaining more confidence in these stocks

PG&E

SentinelOne

Dan Loeb is a veteran hedge fund manager and the CEO of Third Point. Let's take a look at his top three positions as of Q1.

Billionaire Dan Loeb Is Betting Big on These 3 Stocks

Equifax

Morgan Stanley

NIKE

Otis Worldwide

The MS Global Franchise Portfolio (Trades, Portfolio), part of Morgan Stanley's ( MS , Financial) mutual funds, disclosed in a regulatory filing that its top five buys during the first quarter included new positions in Otis Worldwide Corp. ( OTIS , Financial) and Equifax Inc. ( EFX , Financial) and boosts to its holdings in Nike Inc. ( NKE , Financial), LVMH Moet Hennessy Louis Vuitton SE ( XPAR:MC , Financial) and Danaher Corp. ( DHR , Financial).

MS Global Franchise Portfolio's Top 5 1st-Quarter Buys

Danaher has outperformed its benchmark for the past several decades. They successfully apply the concept of extreme focus and profit orientation in their acquisitions.

Danaher: A Holding To Cover An Entire Sector

In this article, I start by explaining that a low-volatility strategy is a great way to generate long-term (outperforming) wealth. Thanks to outperformance in bear markets and strong growth in bull markets, low-volatility stocks tend to be the best performers.

Danaher: When Low-Volatility And High-Dividend Growth Meet

Danaher Corporation (NYSE:DHR ) Bank of America Securities Health Care Conference May 11, 2022 1:00 PM ET Company Participants Rainer Blair - CEO Conference Call Participants Derik De Bruin - Bank of America Mike Ryskin - Bank of America Derik De Bruin [Call Starts Abruptly] I'm the Senior Life Sciences and Diagnostic Tools Analyst at Bank of America with my colleague, Mike Ryskin, up here on the stage. Welcome to Bank of America's 2022 Healthcare Conference live in Las Vegas, which we're all very happy to be out of our shells.

Danaher Corporation (DHR) CEO Rainer Blair Presents at Bank of America Securities Health Care Conference (Transcript)

Consortium aims to speed the development and delivery of customized or 'bespoke' gene therapies WASHINGTON , May 12, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it has joined the Bespoke Gene Therapy Consortium (BGTC). Launched in October 2021, the BGTC will generate gene therapy resources that the research community can use to streamline gene therapy development for rare disorders, making the process more efficient and less costly.

Danaher Joins Bespoke Gene Therapy Consortium (BGTC) for Rare Diseases

WASHINGTON , May 10, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.25 per share of its common stock, payable on July 29, 2022 to holders of record on June 24, 2022. In addition, the Board of Directors has approved a quarterly cash dividend of $12.50 per share of its 5.00% Series B Mandatory Convertible Preferred Stock, payable on July 15, 2022 to holders of record on June 30, 2022.

DANAHER ANNOUNCES QUARTERLY DIVIDENDS

FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #EL--At TIDES 2022, SCIEX, a global leader in life science analytical technologies, and a company of Danaher Corporation (NYSE:DHR), launches the RNA 9000 Purity & Integrity kit, for the BioPhase 8800 system and PA 800 Plus system. As genomic medicine takes center stage and the demand for RNA-based therapeutics and vaccines grows, the integrity and quality of RNA species is increasingly important. Scientists have been faced with complex methods that have low r

RNA 9000 Purity and Integrity Kit Allows for Critical High-Resolution Analysis for mRNA Therapeutics

Danaher's long-term prospects are being ignored because of the near-term speculation around how long the pandemic will last.

Down 25% in 2022: Buy This High-Quality Stock on a Dip?

WASHINGTON , May 4, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Wednesday, May 11, 2022 at 10:00 a.m.

Danaher To Present At Bank Of America Securities Health Care Conference

Danaher Corporation (NYSE: DHR) is a global science and technology conglomerate with more than 20 operating companies.

Put Traders Pile on Underperforming Science and Tech Name

Danaher posted a temporary weakness on its topline growth which snowballed to its margins. It enjoys opportunities outside the pandemic which will support its topline growth.

Danaher Remains Stable And Better Than Its Pre-Pandemic Level

Danaher Corporation (NYSE:DHR) had several weeks of downward pressure on the price. The stock appears to have consolidated in the range between $262 and $297.

Will Danaher reverse the trend of the declining share price after Q1 results?

Danaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Danaher (DHR) Rating Upgrade to Buy

We expect some noise around Covid testing quarter to continue as we work through China lockdowns, we think it's a distraction from Danaher's long-term story.

Danaher gets lift from Covid testing, but core business is also humming

Danaher Corporation (NYSE:DHR ) Q1 2022 Earnings Conference Call April 21, 2022 8:00 AM ET Company Participants John Bedford - Vice President, Investor Relations Rainer Blair - President and Chief Executive Officer Matt McGrew - Executive Vice President and Chief Financial Officer Conference Call Participants Derik De Bruin - Bank of America Vijay Kumar - Evercore ISI Scott Davis - Melius Research Dan Brennan - Cowen Jack Meehan - Nephron Research Patrick Donnelly - Citi Luke Sergott - Barclays Operator Good day. My name is Leo and I will be your conference facilitator this morning.

News for Danaher Stock (DHR)